Single-Patient trial tests heart drug for rare genetic syndrome
NCT ID NCT06534671
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a single intravenous dose of diltiazem, a calcium channel blocker, can shorten the QT interval in adults with Jervell and Lange-Nielsen syndrome, a rare genetic heart condition that increases the risk of dangerous heart rhythms. Only one person participated, and the researchers measured heart activity for up to 35 minutes after the drug was given. The goal was to see if diltiazem could quickly affect the heart's electrical activity.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- diltiazem (a calcium channel blocker given intravenously)
- What this could lead to
- If it works, this could point toward a way to temporarily shorten the QT interval and reduce the risk of dangerous heart rhythms in people with Jervell and Lange-Nielsen syndrome.
- What could go wrong
- This was a very small study with only one participant, so results may not apply to others. It only looked at immediate effects of a single dose, not long-term safety or benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
1 person
The number who actually took part.
- Started
-
Oct 2024
- Finished
-
Oct 2024
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age greater than 18 years * Genetically confirmed diagnosis of Jervell and Lange-Nielsen syndrome * Able to provide written informed consent Exclusion Criteria: * Known hypersensitivity to diltiazem * Pregnancy * Congestive heart failure, angina, preexcitation, or chronic obstructive pulmonary disease * Sick sinus syndrome or atrioventricular block in the absence of a pacemaker/defibrillator * Any clinically significant ongoing medical or surgical condition that might jeopardize the subject's safety or interfere with the conduct of the study in the judgement of the investigator * Baseline systolic blood pressure less than 100 Hg or diastolic blood pressure less than 60 Hg
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Jervell and lange nielsen syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States